OPKO HEALTH, INC.

BU SINESS OVERVIEW We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. ( Pfizer ) for further development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of children and adolescents as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, have been secured in more than 50 markets worldwide, including in the United States, European Union Member States, Japan, Canada, and Australia under the brand name NGENLA . Through our pharmaceutical business, we manufacture and sell Rayaldee , a U.S. Food and Drug Administration ( FDA ) approved treatment for secondary hyperparathyroidism ( SHPT ) in adults with stage 3 or 4 chronic kidney disease ( CKD ) and vitamin D insufficiency. Rayaldee has secured marketing authorizations in 11 European countries, and we are advancing its development in mainland China through our strategic partners. Our subsidiary, ModeX Therapeutics, Inc. ( ModeX ), is a biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious disease candidates.